Emcure Pharmaceuticals

Emcure Pharmaceuticals Limited
Company type	Public
Industry	Pharmaceuticals
Founded	1981; 45 years ago
Founder	Satish Mehta
Headquarters	Pune, India
Area served	Worldwide
Key people	Satish Mehta (Founder)
Products	Tablets, capsules (softgel and hard-gel), injectable medications; therapeutic segments including gynaecology, cardiovascular health, oncology, hematological disorders, HIV antivirals, anti-infectives, vitamins and minerals
Website	www.emcure.com

Adapted from the English Wikipedia article Emcure Pharmaceuticals, available under CC BY-SA 4.0Updated 9 August 2025

Emcure Pharmaceuticals Limited (Emcure) is a global pharmaceutical enterprise based in Pune, India. Its extensive product range encompasses tablets, capsules (both softgel and hard-gel forms), and injectable medications. The company specializes in therapeutic segments including gynaecology, cardiovascular health, oncology, hematological disorders, HIV antivirals, various anti-infectives, as well as vitamins and minerals.

History

Established in 1981 by Satish Mehta, Emcure began with a bank loan of 3 lakh (approximately US$35,000) following his graduation from IIM-A. During the 1990s, the company transitioned from functioning primarily as a contract manufacturing organization to focusing on the production of generic drugs.

In 2006, Emcure entered into licensing collaborations with Bristol-Myers Squibb for Atazanavir and with Gilead Sciences for Tenofovir, participating in their Global Access Programs.

By 2012, Emcure partnered with Roche to locally manufacture anticancer therapies Herceptin and Mabthera in India, aiming to provide cost-effective options for emerging markets.

The following year, in 2013, the company ventured into health foods alongside cricketer MS Dhoni, who also took on the role of brand ambassador.

In 2014, Blackstone divested its 13% equity stake in Emcure to Bain Capital.

In 2021, Emcure separated its US operations, including its subsidiary Heritage Pharmaceuticals, into a new entity named Avet Lifesciences.

The company went public in 2024 through an initial public offering (IPO), securing listings on both NSE and BSE.

Indian facilities

Emcure's manufacturing infrastructure within India comprises:

Solid Dosage plant located at Hinjawadi, Pune – received US FDA approval in 2006 for export to regulated global markets; currently subject to an FDA warning letter.
Small volume parenteral facility at Hinjawadi – approved by both US FDA and UK MHRA; equipped for lyophilization and prefilled syringes; presently under an FDA warning letter.
Oncology injectable manufacturing unit at Hinjawadi – currently under FDA warning letter.
Solid oral dosage plants situated in Jammu and Bhosari.
Active Pharmaceutical Ingredient (API) manufacturing site at Kurkumbh – holds US FDA approval.
Biotechnology manufacturing plant based in Hinjawadi.
Research & Development centers at Gandhinagar and an FDA-approved manufacturing site at Sanand, Ahmedabad.

United States facility

Emcure maintains a production plant and R&D center located in East Brunswick, New Jersey.

AIDS initiative

Under its corporate social responsibility efforts, Emcure runs the "Let's fight AIDS together" program, distributing antiretroviral medications across Africa, Asia Pacific, and CIS territories. Additionally, it supports 'Taal,' a pharmacy operated by individuals living with HIV/AIDS.

Controversies and recalls

In 2016, former leaders of Heritage Pharmaceuticals—previously part of Emcure—were charged by the Department of Justice for engaging in price-fixing involving antibiotics and antidiabetic medications. Heritage Pharmaceuticals entered into a deferred prosecution agreement in 2019 and paid fines exceeding $7 million.

In 2022, HDT Bio Corp filed allegations against Emcure’s subsidiary Gennova accusing theft of COVID-19 vaccine trade secrets; however, this lawsuit was dismissed in 2024.

The USFDA issued a warning letter to Emcure in 2016 citing concerns over data integrity violations at several manufacturing sites.

Notable product recalls include:

In 2010, Pfizer recalled three batches of antibacterial products due to contamination issues.
In 2011, Teva conducted recalls after detecting contamination with Yersinia pestis.
In 2019, two injectable drugs produced by Emcure were withdrawn because of microbial contamination; these were distributed in the US market by Heritage Pharmaceuticals (now Avet Lifesciences).
In 2022, Maharashtra FDA mandated a nationwide recall of Emcure’s injections (500 mg/10 ml) following safety-related concerns.

External links

Official Emcure website